For example, in colon carcinoma CT26 engineered to express CX3CR1, the use of an FKN–CX3CR1 blocking antibody in combination with anti-PD-1 results in enhanced therapeutic activities [37]. Here, CX3CR1 is linked to colon carcinoma.